Adage Capital Partners
KRTX

Adage Capital Partners’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Adage Capital Partners’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-135,000
Closed -$30.4M – 1063
2022
Q3 		$30.4M Sell
135,000
-140,000
-51% -$28.3M 0.08% 286
2022
Q2 		$34.8M Sell
275,000
-125,000
-31% -$14.4M 0.08% 267
2022
Q1 		$50.7M Buy
400,000
+281,406
+237% +$31.7M 0.1% 211
2021
Q4 		$15.5M Buy
+118,594
New +$15.3M 0.03% 568

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners's KRTX Position: Q4 2022 in Review

Adage Capital Partners sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2022, closing a stake of 135,000 shares — an estimated $30.4M sold.

Adage Capital Partners first reported a position in KRTX in Q4 2021 and held it in 4 quarters. The position peaked at $50.7M in Q1 2022. 248 funds tracked by Wall St. Rank hold KRTX as of Q4 2022.

  • Adage Capital Partners reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Adage Capital Partners sold 135,000 Karuna Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $30.4M.
  • Adage Capital Partners first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
  • Adage Capital Partners's Karuna Therapeutics, Inc. Common Stock position peaked at $50.7M in Q1 2022.
  • 248 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Adage Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.